Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Susmita Chakrabarti

Susmita Chakrabarti

Cleveland Clinic Foundation, USA

Title: MOG1, a novel therapeutic agent for Cardiac traffickopathies

Biography

Biography: Susmita Chakrabarti

Abstract

Despite tremendous improvements in its prevention and treatment, cardiac-arrhythmias are themajor cause of morbidity and mortality worldwide accounting for >1.2 million hospitalizations and 400,000 sudden-deaths each year in the United States.The cardiac voltage gated sodium channel, Nav1.5, is crucial for maintaining normal cardiac rhythm. Loss-of-function mutations in the Nav1.5-encoding gene SCN5A cause a vast array of cardiac disorders including Brugada Syndrome (BrS), Sick Sinus Syndrome (SSS), Dilated Cardiomyopathy (DCM), Cardiac Conduction Disease (CCD) and Atrial Fibrillation (AF). However, no effective treatment is available for these syndromes, except for invasive implantation of defibrillators or pacemakers in some cases. Defects in cell-surface-trafficking of ion-channels have been demonstrated to be a unique molecular mechanism underlying a variety of arrhythmic disorders. As SCN5A-mutations causing BrS, DCM and SSS act by loss-of-function; agents increasing cardiac-sodium-current (INa) may aid towards safe, effective treatment. In 2008, we reported that a 20kD protein MOG1 is a novel cofactor modulating Nav1.5-function. In 2013, we demonstrated the therapeutic potential of MOG1 in vitro to rescue the Nav1.5-trafficking-defects and reduced INa associated with BrS, DCM and SSS. We are currently evaluating the therapeutic potential of MOG1 in vivo. Reduced INa has also been associated with inherited cardiovascular disorders like myocardial infarctions/ ischemia and heart-failure. Thus, the MOG1-therapy to facilitate membrane-trafficking of Nav1.5 may be utilized for the trafficking-defective subset of cardiac channelopathies.